Dr. André Boulet has extensive experience in drug development, regulatory affairs, market access, financing, and restructuring in the pharmaceutical and biotech fields. A seasoned entrepreneur, he stands out by combining his strengths in applied science, business, and finance.
Within Devonian Health Group, he has raised more than $50M in private and public equity, completed a phase I study in healthy volunteers, a phase IIa proof-of-concept study in mild to moderate ulcerative colitis, and a phase II clinical study in adults with mild to moderate atopic dermatitis using the company’s flagship product, Thykamine™.
The company also offers a complete line of patented anti-aging products.
Prior to this endeavour, he was managing partner of SIPAR’s biotech unit, a $400M private investment firm. Before SIPAR, Dr. Boulet was managing partner at BioCapital mutual fund, and prior to that, he was partner at BioCapital III LP (“BioCapital”), a Canadian biotech venture capital company.
Throughout his career, Dr. Boulet has acquired international expertise in drug development, regulatory affairs, and health economics within Hoechst Marion Roussel, Marion Merrell Dow Canada, and Laboratoires Nordic (now Sanofi).
Dr. Boulet holds a Bachelor’s degree in Medical Biology from the University of Quebec in Trois-Rivières, a Master’s degree in Experimental Medicine/Immunology-Immunochemistry, and a PhD in Physiology-Endocrinology from Laval University in Quebec City. He also completed post-doctoral training at the University of Pennsylvania (USA) in Biochemistry-Biophysics, as well as a training program in Health Economics at York University (UK).